MedTrace Logo

Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomarkers From Peripheral Blood and Exhaled Air and Its Effect on the Outcome of Therapy

NCT05270278 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 89

Last updated 2024-02-23

No results posted yet for this study

Summary

The goal of this study is to identify reliable, valid, easily measurable, interpretable, and useful biomarkers in peripheral blood and exhaled air by people with severe asthma for a more accurate description of the pathogenetic processes of asthma-related to the inflammatory endotype and the choice of biologic therapy.

Conditions

  • Asthma; Eosinophilic
  • Asthma Chronic
  • Bronchial Asthma
  • Asthma, Bronchial

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Value Outcomes Ltd.

    lead OTHER

Principal Investigators

  • Jakub Novosad, MUDr.,Ph.D. · Fakultní nemocnice Hradec Králové

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-16
Primary Completion
2023-03-31
Completion
2023-03-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05270278 on ClinicalTrials.gov